ARWR Arrowhead Pharmaceuticals, Inc.
ARWR Arrowhead Pharmaceuticals, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $64.80 · VWAP $66.93 · -16.5% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster Director + 1 other sold $1.2M, Aug 20
Coverage
1 watchlist
ARWR Price Structure
Loading timeframes…
Peers
Every watchlist ARWR belongs to, members best 30-day change first — ARWR highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $75M, diluted EPS -$1.36, net income -$194M (SEC filing). Across the print the stock moved +0.9% (close before → first close after).
full note →Against street estimates
How ARWR's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about ARWR from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 2 days ago · Oct 15
- Investors | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Q3 2026 Earnings Results and Report
- Arrowhead Pharmaceuticals Corp. (ARWR) Stock Price Today - The Wall Street Journal
- Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
- Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
ARWR research tape
45 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.